Objective Premature discontinuation of antiplatelet therapy (APT) increases the risk of thrombosis in patients who have undergone placement of a drug-eluting stent for acute coronary syndrome (ACS). The goal of the present study was to identify predictors of patients who would prematurely discontinue APT following stent implantation. Methods One-hundred and sixty-one ACS patients who underwent percutaneous coronary intervention in our institution between November 2004 and September 2008 were enrolled in this study. Results Over the 12-month follow-up period, 18 patients (11.2%) discontinued APT. Among baseline demographic and laboratory variables, multivariate analysis revealed that mean corpuscular hemoglobin (MCH) level was an independent risk factor for APT discontinuation (OR: 0.738, p=0.017). Kaplan-Meier survival analysis showed that the incidence of APT discontinuation was significantly higher in patients with low MCH (<30.0 pg) than in patients with high MCH (!30.0 pg) (p=0.0006). Conclusion Low baseline MCH level was a predictor of APT discontinuation in ACS patients. Thus, careful consideration should be made before employing a drug-eluting stent in patients with low MCH levels.
Introduction
Stent thrombosis (ST) is a serious complication that can occur in the setting of premature discontinuation of antiplatelet therapy (APT) (1) (2) (3) in patients who have undergone placement of a drug-eluting stent (DES) for coronary artery disease or acute coronary syndrome (ACS) (4, 5) . Since the risk of ST following DES placement is increased for at least 1 year, the American Heart Association (AHA) and American College of Cardiology (ACC) guidelines recommend continuation of dual APT (aspirin and clopidogrel) for at least 1 year after implantation of a DES (6) . Regardless, the PREMIER study revealed that nearly one in seven ACS patients discontinued APT within 30 days after DES placement (7). The ability to predict which patients will prematurely discontinue APT would be of great benefit in determining whether patients should receive a bare-metal stent (BMS) or a DES during percutaneous coronary intervention (PCI), because shorter durations of APT are recommended for bare metal stents, resulting in a shorter time course for the risk of ST. Some studies have reported that APT-related bleeding could be predicted on the basis of gender, age, renal function, white blood cell count, red blood cell count, myocardial infarction (8) , inflammation (9) , and body mass index (10) , in patients who underwent PCI, but these observations do not describe the full population at risk for APT discontinuation. The goal of the present study was to identify predictors of patients who would prematurely discontinue APT following stent implantation for ACS.
Materials and Methods

Study population
From November 2004 to September 2008, 178 ACS patients admitted to our institution for PCI were consecutively recruited. The study was conducted according to the principles of the Declaration of Helsinki, and all the patients signed a written informed consent to be included in this trial. Patients included those with ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), and unstable angina. All patients had ischemic chest discomfort with STsegment elevation or depression of >0.5 mm or with T wave inversion in two or more leads. A diagnosis of STEMI and NSTEMI was based on chest pain lasting !30 min, and an increased serum creatine kinase (CK)-MB fraction. A diagnosis of STEMI also required the presence of new STsegment elevation in at least two leads. The following data were also recorded at baseline: clinical characteristics (e.g., sex, age, STEMI, multi vessel and/or LMT, low ejection fraction, patients with DES, body length, body weight, body mass index, systolic blood pressure, diastolic blood pressure, heart rate and living alone), medications (e.g., Dual antiplatelet therapy, warfarin, statin, proton pump inhibitors and H2-blockers), laboratory data (e.g., white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, total protein, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, CK, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, hemoglobin A1c, blood urea nitrogen, Na, K, Cl and C-reactive protein), and cardiac risk factors (e.g., smoking status, dyslipidemia, hypertension, diabetes mellitus and hyperurecemia).
Estimated glomerular filtration rate (eGFR) was calculated by the Modification of Diet in Renal Disease equation (11) 
Coronary intervention and antiplatelet therapy
In all cases, PCI was performed after admission, with interventions consisting of placement of a BMS, DES, or plain old balloon angioplasty (POBA) without stent placement at the discretion of the interventional cardiologist. Patients who did not undergo DES placement during initial PCI for treatment of a culprit lesion but who did undergo DES placement later during the hospitalization for treatment of a non-culprit lesion were still included in Patients with DES. A standard dose of aspirin (81 mg or 100 mg daily) was given to all patients, except for those with recent bleeding events. Patients who received a BMS or DES were also given a thienopyridine antiplatelet agent (ticlopidine 200 mg daily or clopidogrel 300 mg loading dose followed by 75 mg daily) or cilostazol 200 mg daily. In all PCI procedures (BMS, DES or POBA), all antiplatelet agents were continued during the follow-up period.
Follow-up and definition of APT discontinuation
APT discontinuation was defined as cessation of APT therapy due to non-cardiac surgery, major bleeding, biopsy or any other reasons. Major bleeding was defined by TIMI major bleeding criteria, as previously described (12) . In the present study, drug noncompliance was excluded from APT discontinuation. All ACS patients who received PCI were given drug administration guidance to prevent drug noncompliance. Follow-up data were obtained from medical records and personal interviews and were available for >90% of patients.
Statistical analysis
Statistical analysis was performed with SPSS version 19. Comparisons were performed with chi-square statistics, unpaired Student's t-test, or analysis of variance. Multivariate analysis was performed using a Cox proportional hazards model. The candidate variables that were entered into the model included patients' backgrounds (age, gender and body mass index), the presence or absence of STEMI, baseline laboratory values [mean corpuscular hemoglobin (MCH), white blood count, platelet count, eGFR and C-reactive protein] and the presence or absence of taking warfarin. Analysis results were verified with stepwise forward or backward Cox's regression. A p-value <0.05 was considered statistically significant.
Receiver operating characteristic (ROC) curves of baseline laboratory data were drawn to obtain the area under the ROC curve (AUC) and the optimal cutoff point for the prediction of APT discontinuation based on baseline laboratory data. The optimal cutoff point was defined as the point on the ROC curve nearest to the point where both sensitivity and specificity were the highest. Event rate curves were drawn using the Kaplan-Meier method, and the log-rank test was used to compare event rates between two groups.
Results
Follow-up and incidence of APT discontinuation
During the follow-up period, 178 patients treated by PCI were enrolled. APT discontinuation was assessed in 161 (90.4%) of the 178 patients (Fig. 1) . Ten patients (4.5%) were lost to follow-up, five patients (2.8%) died shortly after admission, and two patients who underwent coronary artery bypass grafting after PCI were not included in the final analysis. Discontinuation of APT was observed in 18 patients (11.2%) of 161 patients. Reasons for discontinuation included major bleeding complications in eight patients and the need for biopsy or non-cardiac surgery in 10 patients. Of the 18 patients who discontinued APT, nine patients had cancer, with a diagnosis of cancer preceding PCI in three of these nine patients. Fig. 2 shows the cumulative rate of antiplatelet therapy discontinuation during the study period. APT discontinued events occurred consecutively over time.
Patient characteristics
The mean (±SD) age was 68.4 ± 11.5 years (range, 37-90 years). Of the 161 patients, 119 were males, 63 (39.1%) had STEMI, 72 (44.7%) received a DES, and 57 patients (35.4%) had multi-vessel disease. Further, 39 patients had chronic kidney disease, and five patients were receiving chronic dialysis.
A total of 155 patients (96.2%) received dual APT, consisting of 144 patients (89.4%) receiving aspirin + thienopyridine, and 11 patients (6.8%) receiving aspirin + cilostazol. Another 42 patients (26.1%) received warfarin, and 145 patients (90.0%) received H2-blockers or proton pump inhibitors.
Relationship between APT discontinuation and baseline patient characteristics, medications or laboratory data Table 1 summarizes the relationship between the baseline characteristics and APT discontinuation. There was no significant difference in baseline characteristics when comparing patients who discontinued APT and those that continued APT. Table 2 summarizes the relationship between baseline medications and APT discontinuation. There was no significant difference in baseline medications between APT discontinued group and continued group. Table 3 summarizes the relationship between laboratory values and APT discontinuation. Hemoglobin (p=0.003), mean corpuscular volume (p= 0.040), and mean corpuscular hemoglobin (MCH) (p=0.002) were lower and platelet counts were higher (p=0.037) in patients who discontinued APT when compared with patients who continued APT. Plasma C-reactive protein level (p= 0.051) tended to be higher in patients who discontinued APT when compared with patients who continued APT. These results suggest that MCH was the strongest predictor of APT discontinuation.
Multivariate analysis of potential predictors of APT discontinuation
Data from multivariate analysis of potential predictors of APT are summarized in Table 4 . This analysis showed that age, sex, STEMI, body mass index, white blood cell count, platelet count, eGFR, C-reactive protein and APT with warfarin were not significantly related to APT discontinuation. However, low MCH level was significantly associated with APT discontinuation [odds ratio, 0.738; 95% confidence interval, 0.575-0.946; p=0.017]. 
Cutoff points of MCH for predicting APT discontinuation
A ROC curve of baseline MCH level was drawn to obtain AUC and the optimal cutoff point to predict APT discontinuation (Fig. 3) . AUC was 0.67 (95% Confidence interval 0.51 to 0.83), and the optimal cutoff point for diagnosing APT discontinuation was 29.85 pg. Therefore, we defined the MCH cutoff point for predicting APT discontinuation as <30.0 pg.
Relationship between cause of APT discontinuation and MCH levels
By subgroup analysis, APT discontinued group with major bleeding event had significantly lower MCH level compared with APT continued group (p=0.004) (Fig. 4) . Even in APT discontinued group without major bleeding event who had non-cardiac surgery or biopsy, MCH level tended to be lower than in APT continued group (p=0.056). There is no significant difference in MCH levels between APT discontinued group with major bleeding and without major bleeding. Fig. 5 shows the Kaplan-Meier Curves for discontinuation of APT. During the 1-year follow-up period, the rate of APT discontinuation was higher in the low MCH group (<30.0 
Comparison of APT discontinuation between patients with high and low MCH
Discussion
Over the 12-month follow-up period, 18 patients (11.2%, or roughly 1 in 9 patients) discontinued APT, including 8 patients with major bleeding and 10 patients requiring bi- opsy or non-cardiac surgery. Multivariate analysis revealed that MCH level (odds ratio, 0.781, p=0.034) was an independent risk factor for APT discontinuation. Kaplan-Meier survival analysis showed that the incidence of APT discontinuation was higher in patients with low MCH than in patients with high MCH (p=0.0006). The incidence of APT discontinuation in the present study is consistent with those reported in previous studies of patients with coronary artery disease (13, 14) .
In the present study, low MCH level was associated with APT discontinuation. This value can be easily measured when patients with ACS present to the Emergency Department (ED). A multicenter study recently reported that individual-and hospital-level variables predicted APT discontinuation after DES implantation (15) but did not include an analysis of baseline laboratory data. Therefore, this is the first study to investigate whether laboratory data that are easily acquired upon first presentation to the ED could be predictors of APT discontinuation.
Anemia is associated with a poor prognosis in patients with ACS (16, 17) . The HORIZONS-AMI trial reported that baseline anemia was a strong predictor for major bleeding and death in patients with ACS who underwent PCI (18) . In the present study, eight patients (5.0%) experienced major bleeding that necessitated discontinuation of APT during the 12-month follow-up period. It is likely that baseline anemia is an indicator of occult chronic bleeding and is therefore associated with a higher risk of bleeding-related discontinuation of APT in ACS patients. The other 10 patients (6.2%) that discontinued APT in the present study required surgical procedures for malignant diseases.
Among hematologic parameters, low MCH was a stronger predictor of APT discontinuation relative to red blood cell count, hemoglobin, hematocrit, mean corpuscular volume and mean corpuscular hemoglobin concentration. This may be due to the fact that MCH is one of the earliest and sensitive indicators of iron deficiency (19-21) ; thus, low MCH was likely an indicator of occult chronic bleeding.
Because ACS patients often require urgent transfer from the ED to cardiac catheterization, interventional cardiologists may not have sufficient time to explore the relative risks and benefits of DES implantation in individual patients. The present study demonstrated that MCH, which can be determined within approximately 30 minutes after presentation to the ED, may be a useful tool to help guide the choice between a DES and a BMS.
The present study has several important limitations. First, patients were enrolled from a single center. Second, the sample size was relatively small. Third, we did not perform analysis regarding sociodemographic factors. Fourth, this study did not perform a gender-based analysis. Future prospective studies with large cohorts are needed to confirm the utility of low MCH level in predicting discontinuation of APT following PCI for ACS.
Conclusion
Low baseline MCH level was a predictor of APT discontinuation in ACS patients. Thus, careful consideration should be made before employing a DES in patients with low MCH levels.
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